Cargando…

Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition

BACKGROUND: One of the leading causes of death and illness within the agriculture industry is through unintentionally ingesting or inhaling organophosphate pesticides. OP intoxication directly inhibits acetylcholinesterase, resulting in an excitatory signaling cascade leading to fasciculation, loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapleau, Richard R, Robinson, Peter J, Schlager, John J, Gearhart, Jeffery M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209019/
https://www.ncbi.nlm.nih.gov/pubmed/25273339
http://dx.doi.org/10.1186/1742-4682-11-42
_version_ 1782341205430894592
author Chapleau, Richard R
Robinson, Peter J
Schlager, John J
Gearhart, Jeffery M
author_facet Chapleau, Richard R
Robinson, Peter J
Schlager, John J
Gearhart, Jeffery M
author_sort Chapleau, Richard R
collection PubMed
description BACKGROUND: One of the leading causes of death and illness within the agriculture industry is through unintentionally ingesting or inhaling organophosphate pesticides. OP intoxication directly inhibits acetylcholinesterase, resulting in an excitatory signaling cascade leading to fasciculation, loss of control of bodily fluids, and seizures. METHODS: Our model was developed using a discrete, rules-based modeling approach in NetLogo. This model includes acetylcholinesterase, the nicotinic acetylcholine receptor responsible for signal transduction, a single release of acetylcholine, organophosphate inhibitors, and a theoretical novel medical countermeasure. We have parameterized the system considering the molecular reaction rate constants in an agent-based approach, as opposed to apparent macroscopic rates used in differential equation models. RESULTS: Our model demonstrates how the cholinergic crisis can be mitigated by therapeutic intervention with an acetylcholinesterase activator. Our model predicts signal rise rates and half-lives consistent with in vitro and in vivo data in the absence and presence of inhibitors. It also predicts the efficacy of theoretical countermeasures acting through three mechanisms: increasing catalytic turnover of acetylcholine, increasing acetylcholine binding affinity to the enzyme, and decreasing binding rates of inhibitors. CONCLUSION: We present a model of the neuromuscular junction confirming observed acetylcholine signaling data and suggesting that developing a countermeasure capable of reducing inhibitor binding, and not activator concentration, is the most important parameter for reducing organophosphate (OP) intoxication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1742-4682-11-42) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4209019
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42090192014-10-28 Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition Chapleau, Richard R Robinson, Peter J Schlager, John J Gearhart, Jeffery M Theor Biol Med Model Research BACKGROUND: One of the leading causes of death and illness within the agriculture industry is through unintentionally ingesting or inhaling organophosphate pesticides. OP intoxication directly inhibits acetylcholinesterase, resulting in an excitatory signaling cascade leading to fasciculation, loss of control of bodily fluids, and seizures. METHODS: Our model was developed using a discrete, rules-based modeling approach in NetLogo. This model includes acetylcholinesterase, the nicotinic acetylcholine receptor responsible for signal transduction, a single release of acetylcholine, organophosphate inhibitors, and a theoretical novel medical countermeasure. We have parameterized the system considering the molecular reaction rate constants in an agent-based approach, as opposed to apparent macroscopic rates used in differential equation models. RESULTS: Our model demonstrates how the cholinergic crisis can be mitigated by therapeutic intervention with an acetylcholinesterase activator. Our model predicts signal rise rates and half-lives consistent with in vitro and in vivo data in the absence and presence of inhibitors. It also predicts the efficacy of theoretical countermeasures acting through three mechanisms: increasing catalytic turnover of acetylcholine, increasing acetylcholine binding affinity to the enzyme, and decreasing binding rates of inhibitors. CONCLUSION: We present a model of the neuromuscular junction confirming observed acetylcholine signaling data and suggesting that developing a countermeasure capable of reducing inhibitor binding, and not activator concentration, is the most important parameter for reducing organophosphate (OP) intoxication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1742-4682-11-42) contains supplementary material, which is available to authorized users. BioMed Central 2014-10-02 /pmc/articles/PMC4209019/ /pubmed/25273339 http://dx.doi.org/10.1186/1742-4682-11-42 Text en © Chapleau et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chapleau, Richard R
Robinson, Peter J
Schlager, John J
Gearhart, Jeffery M
Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title_full Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title_fullStr Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title_full_unstemmed Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title_short Potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
title_sort potential new therapeutic modality revealed through agent-based modeling of the neuromuscular junction and acetylcholinesterase inhibition
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209019/
https://www.ncbi.nlm.nih.gov/pubmed/25273339
http://dx.doi.org/10.1186/1742-4682-11-42
work_keys_str_mv AT chapleaurichardr potentialnewtherapeuticmodalityrevealedthroughagentbasedmodelingoftheneuromuscularjunctionandacetylcholinesteraseinhibition
AT robinsonpeterj potentialnewtherapeuticmodalityrevealedthroughagentbasedmodelingoftheneuromuscularjunctionandacetylcholinesteraseinhibition
AT schlagerjohnj potentialnewtherapeuticmodalityrevealedthroughagentbasedmodelingoftheneuromuscularjunctionandacetylcholinesteraseinhibition
AT gearhartjefferym potentialnewtherapeuticmodalityrevealedthroughagentbasedmodelingoftheneuromuscularjunctionandacetylcholinesteraseinhibition